Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma.
Xiong J, Cheng S, Gao X, Yu SH, Dai YT, Huang XY, Zhong HJ, Wang CF, Yi HM, Zhang H, Cao WG, Li R, Tang W, Zhao Y, Xu PP, Wang L, Zhao WL.
Xiong J, et al. Among authors: cao wg.
Signal Transduct Target Ther. 2024 Mar 6;9(1):62. doi: 10.1038/s41392-024-01782-8.
Signal Transduct Target Ther. 2024.
PMID: 38448403
Free PMC article.
Clinical Trial.